Luye Pharma Group (HKG:2186) completed patient enrollment for its Phase 3 clinical trial of Ruoxinlin(r) (Toludesvenlafaxine) in China for treating generalized anxiety disorder (GAD), according to a Hong Kong bourse filing Monday.

The multicenter, randomized, double-blind, placebo-controlled trial enrolled 555 participants, with the primary endpoint measuring change in Hamilton Anxiety Scale (HAM-A) scores by week eight.

Luye plans to submit its marketing authorization application by the end of this year.

Shares of the pharmaceutical firm gained over 1% in Monday afternoon trade.